1MRNA Stock Chart & Stats
€127.06
€0.97(2.01%)
At close: 4:00 PM EDT
€127.06
€0.97(2.01%)
Day’s Range― - ―
52-Week Range€19.38 - €188.54
Previous CloseN/A
Volume3.18K
Average Volume (3M)34.83K
Market Cap
€80.11B
Enterprise Value€24.02B
Total Cash (Recent Filing)€5.14B
Total Debt (Recent Filing)€1.29B
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Oct 29, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume40,051
30 Day Avg. Volume34,828
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€95.31Price Target Upside-24.99% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-7.42
Revenue Forecast (FY)€1.87B
Bulls Say, Bears Say
Bulls Say
Respiratory Portfolio ExpansionRegulatory progress across flu and respiratory vaccines broadens Moderna beyond a single COVID product and creates additional commercial opportunities. Expanded approvals and procurement access can support a more diversified revenue base as the company builds a recurring seasonal vaccine portfolio.
Oncology Pipeline AdvancementLong-duration clinical data and full enrollment in a pivotal melanoma study indicate meaningful progress toward oncology commercialization. Success would extend Moderna’s mRNA platform into a large therapeutic market and reduce reliance on infectious-disease products over time.
Manageable Leverage And Cost DisciplineLow-to-moderate leverage provides financial flexibility while management is reducing expected operating and cash costs. This combination gives Moderna more capacity to fund pipeline development and absorb revenue volatility than a heavily indebted balance sheet would allow.
Bears Say
Deeply Negative ProfitabilityPersistent negative margins show that the current cost base is not aligned with Moderna’s post-pandemic revenue run-rate. Until operating economics improve, additional product growth may not translate into sustainable earnings, leaving the business dependent on its cash reserves.
Revenue Concentration And Decline RiskThe revenue outlook remains exposed to declining COVID vaccination demand, while several expected products contribute no 2026 revenue under guidance. This limits near-term diversification and makes the recovery dependent on uptake of newer respiratory and pipeline products.
Norovirus Clinical SetbackMissing early success criteria delays clarity on a potentially important vaccine program and pushes confirmation into later enrollment and seasonal data collection. The setback increases development uncertainty and postpones any possible contribution from norovirus to portfolio diversification.
Moderna News
1MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €19.38 and its highest was €188.54 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is €80.11B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 17 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -€1.757 earnings per share for the quarter, beating the consensus estimate of -€1.812 by €0.055.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -0.98.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€1.757 in its last earnings report, beating expectations of -€1.812. Following the earnings report the stock price went up 0.533%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in IT:1MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€95.31 (-24.99% Downside)
€95.31 (-24.99% Downside)
Blogger Sentiment
Neutral
IT:1MRNA Sentiment 55%
Sector Average 67%
Sector Average 67%
News Sentiment
Bullish
Bullish news 69%
Bearish news 31%
Bearish news 31%
Technicals
SMA
Positive
20 days / 200 days
Momentum
717.29%
12-Months-Change
Fundamentals
Return on Equity
-39.20%
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
1MRNA Company Deck
1MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all IT:1MRNA earnings summaries1MRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
1MRNA Stock 12 Month Forecast
Average Price Target
€95.31
▼(-24.99% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―